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Abstract
Objective: Melanoma has been shown in numerous studies to be associated with sun exposure, and with host
phenotypic factors of genetic origin. In this study we use information from a large series of incident cases of
melanoma from an international population-based study to examine the patterns of incidence of melanoma in the
first-degree relatives of these cases.
Methods: A total of 2508 incident cases of melanoma provided information on basic demographic data and
pigmentary characteristics, in addition to detailed information on family history of melanoma. These data were
used to examine the incidence rates ratios of melanoma in the relatives of cases in relation to population rates, and
also with respect to phenotypic characteristics of the probands that have been shown to be associated with
melanoma: mole counts, hair color, eye color, and skin sensitivity to the sun.
Results: The incidence rates reflect the underlying patterns of incidence in the source populations, with generally
higher rates in the Australian sample, low rates in Italy, and intermediate rates in the USA and Canada. Also, rates
are higher in men than in women, except at very young ages. Phenotypic characteristics of the probands were only
weakly associated with the observed rates in the relatives although there is a strong inverse association with age at
diagnosis. Cumulative risk of melanoma rises to 6.9% (6.1%) at age 80 in male (female) first-degree relatives of
cases, and to 10.8% (9.5%) in relatives of cases diagnosed before age 50.
Conclusions: Relatives of cases diagnosed with melanoma are at considerable lifetime risk of the disease, especially if
the case is diagnosed at a young age.
Introduction
In 1999, a group of investigators initiated a population-
based international case–control study to examine
genetic risk factors for melanoma and their possible
interactions with sun exposure (the Genes, Environ-
ment, and Melanoma (GEM) study). In this report we
use data from this study to examine the reported
incidence of melanoma in the birth cohort of first-
degree relatives of probands with a first primary
diagnosis of melanoma.
This strategy provides a rich resource of information,
since the incidence of melanoma in the relatives of
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subjects with melanoma is substantially higher than the
population incidence of the disease. We are able to
examine the pattern of incidence rates in these subjects
with respect to the geographical regions from which the
corresponding probands were sampled, regions with
wide variations in the incidence of melanoma [1, 2]. We
are also able to estimate the cumulative risk of mela-
noma in relatives of cases diagnosed with the disease.
Melanoma is associated with sun exposure, the only
well-established environmental risk factor [3]. In addi-
tion, numerous studies have demonstrated associations
between melanoma and pigmentary characteristics that
are likely to have genetic origin. Several of these, such as
hair color, eye color, and propensity to freckle were
examined in a meta-analysis that demonstrated signif-
icant effects for each of these factors [4]. Stronger
associations have been demonstrated in many studies for
total nevi counts, although no meta-analysis of this risk
factor has been conducted to date. Rare mutations in
CDKN2A encoding for the protein p16 has been shown
to be a strong risk factor in melanoma families [5–7].
Data from our study offer the opportunity to examine
the relationship between the presence of these factors in
the melanoma cases that are the probands for our study
and the incidence of melanoma in their first-degree
relatives, and in this report we focus on factors reported
via interview. All cancer risk factors are over-repre-
sented among incident cases, and so relatives of cases
with identified risk factors of genetic origin should also
have elevated risk. [8, 9]. Our results offer insights into
which subsets of the population are at sufficiently
elevated risk of melanoma to be targeted for focussed
cancer prevention strategies.
Methods
The GEM study involves the population-based ascer-
tainment of incident cases of melanoma in nine geo-
graphic regions of the world: New South Wales
(Australia); Tasmania (Australia); British Columbia
(Canada); Ontario (Canada); Torino (Piemonte, Italy);
California (Orange County and San Diego, USA);
Michigan (USA); New Jersey (USA); North Carolina
(USA). The present report is limited to incident cases of
first primary invasive melanoma diagnosed during a
6-month period January 1, 2000–June 30, 2000 with the
following exceptions: the whole of 2000 in California
and North Carolina; from January 1, 2000 to August 31,
2000 in Ontario, and from June 1, 2000 to May 31, 2001
in Torino, Italy. Risk factors of interest were measured
by data collected from a self-administered question-
naire, a telephone interview, and by testing DNA from
buccal cells or blood. The study protocol was approved
by the Coordinating Center’s Institutional Review
Board (at Memorial Sloan-Kettering Cancer Center in
New York), and by those at each of the contributing
sites.
These cases, hereafter referred to as the ‘probands’ for
the current analysis, were identified by the relevant
population-based cancer registry. Physician approval
was obtained prior to subject contact. Research staff
obtained informed consent and a self-administered
questionnaire to obtain basic demographic data, pig-
mentary characteristics, and residence, occupation and
vacation history. Subsequently, a telephone interview
lasting approximately one hour was conducted in which
detailed information was obtained on the family history
of melanoma and other cancers, including non-mela-
noma skin cancer, in all first-degree relatives of the
probands. Genuine first-degree relationships were care-
fully distinguished within the interview. Data obtained
include the age at diagnosis of melanoma in those
relatives who had experienced the disease, and the
current age or age at death of all relatives. Information
on hair color (as a teenager), eye color, skin color
(without tanning), freckling (as a child), extent of moles
on the body, and skin sensitivity of the probands was
also obtained, but was not obtained for relatives. The
skin sensitivity questions were phrased to ask the subject
what would happen to one’s skin if exposed to bright
sunlight for the first time in summer for one hour in the
middle of the day without protection [10]. The subject
was also asked what would happen with repeated
exposure to bright sunlight in summer without protec-
tion. For our analyses, we have characterized sensitivity
in two dimensions: propensity to burn, defined as severe
sunburn with blistering and/or peeling after one hour of
unprotected sun exposure, and propensity to tan,
defined as moderate or deep tan after repeated sun
exposure. Probands were asked to have relatives or
friends to count the number of moles on their backs.
Pathology slides were obtained and were reviewed by
one of three central pathologists (or by two if there was
disagreement between the original diagnosis and that of
the first review pathologist).
All data were collected and sent to the Coordinating
Center on a routine basis and maintained in a database.
Research staff at the Coordinating Center carried out
data quality assurance. Data from the self-administered
questionnaire and telephone interview were transferred
either by machine-scannable forms or electronically.
Simple univariate analysis and logical algorithms were
used to check for logical inconsistencies in the data.
All data analyses involve the incidence rates of mela-
noma in the identified first-degree relatives (biological
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parents, full siblings, children), and these rates exclude the
proband, except insofar as the analyses involve subgroups
defined by characteristics of the proband. Person-years at
risk of melanoma were determined for each relative up to
the age at diagnosis of melanoma if there was an
occurrence of the disease, or else to the current age or
age at death.We report these rates stratified by age (<30,
30–49, 50–69, ‡70), as cumulative rates up to age 85, and
also standardized to a common standard population, the
2000 population of the USA, for comparability with the
convention used in USA national statistics [11]. We used
this in preference to a world standard, since the geo-
graphical regions contributing to the study have popula-
tions with an age structure similar to the USA. The
familial relative risk (standardized incidence ratio) is the
ratio of a rate obtained in this manner to the correspond-
ing standardized rate in the population from which the
probands were derived. Establishing the baseline rates
presents an analytic dilemma since the calendar time
period in which the melanomas occurred varied greatly
among the reported events in the relatives, and since
population rates of melanoma have been increasing,
especially in the older age groups. Since the average year
of diagnosis of melanoma reported in the relatives was in
the region of 1990 we elected to use population rates for
the period 1990–1994 as the benchmark for our estimates
of incidence rates and cumulative risks, and in the
denominators of our calculations of the familial relative
risk. These rates were obtained from the population
registries in each of the geographic regions contributing
to the GEM study.
To examine the relationship of the incidence rates
with pigmentary and other characteristics of the pro-
bands we initially compare the characteristics individu-
ally using unadjusted and age-standardized rates. To
offset potential confounding we performed a Poisson
regression analysis that permits simultaneous estimation
of the various rate ratios [12]. In this analysis adjustment
was made for residual clustering of outcomes within
families, which has been demonstrated in a previous
similar study of melanoma [13], by using a mixed model
that includes a random effect for each family (normally
distributed). These analyses were conducted using STA-
TA statistical software [12]. To adjust our cumulative
risk projections to project risk in subsets, e.g., relatives
of probands under 30 years of age, we make use of the
fact that the risk in the ith risk category is given by
ri ¼ r/i=Rki¼1 pi/i; where/2; . . . ;/k are the rate ratios
relatives to the baseline category, /1 ¼ 1 by definition,
p1; . . . ; pk are the corresponding prevalences of the
categories, and r is the overall average risk, i.e.,
r ¼ R piri:
Results
Details of the probands are provided in Table 1. A total
of 2508 incident cases of first primary melanoma
consented to participate in the GEM study. Of these
we were able to obtain data on phenotypic character-
istics on 2491 probands (99.3%), and data on family
history of melanoma and sun sensitivity characteristics
on 2501 probands (99.7%). The median age at mela-
noma diagnosis is 59 years (63 for men and 53 for
women). As expected there is a male predominance.
Virtually all of the probands are of white, European
ancestry (90%). Approximately 62% of the probands
were accrued from North America, 6% from Torino,
and the remainder from Australia (32%). Data are
available on 16,216 first-degree relatives of these pro-
bands. Thirty-nine of the probands reported that they
were adopted. All of the other probands, and all 39 of
the adoptees, provided information on at least one
known biological first-degree relative. A total of 340
cases of melanoma are reported in these relatives, 173 in
4966 parents, 131 in 6158 siblings, and 36 in 5085
children. The preponderance have been reported in
Table 1. Characteristics of probands
Number of probands: Frequencies
Total consented 2508
Telephone interviewa 2501 (99.7%)











New South Wales 725 (29%)
Tasmania 80 (3%)
British Columbia 119 (5%)
Ontario 432 (17%)
Torino 148 (6%)
California (Irvine) 218 (9%)
Michigan 320 (13%)
New Jersey 171 (7%)
North Carolina 288 (11%)
a Data on family history and sun sensitivity.
b Data on phenotypic characteristics.
c Restricted to analyzable cases, i.e., those with data available on
family history.
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parents and siblings, as we would expect, given the
relatively young age of children of probands. Due to the
relatively small numbers of events, siblings and other
first-degree relatives are aggregated in all subsequent
presentations.
The age- and sex-specific incidence rates in the
relatives are presented in Table 2, separately for Aus-
tralia and North America. (The results from Italy are
not included in Table 2. There were only six reported
melanomas among the Italian relatives, where the
population rates are much lower, and so the data are
too sparse to provide reliable estimates of rates.)
Consistent with the recognition that melanoma aggre-
gates in families, the rates are substantially higher than
the corresponding population rates, but they reflect the
typical trends of those populations. That is, the rates in
Australia are generally higher than in North America
(except for elderly men and women), and the rates in
women are slightly higher than in men at young ages,
but lower as age increases. The degree of elevation in
incidence in these relatives of cases can be characterized
by the familial risk ratio (FRR), the ratio of the
standardized rate in relatives to the population stan-
dardized rates. The FRR is 1.5 (1.1–1.8) in Australian
males, 3.2 (2.6–3.9) in North American males, 2.0 (1.6–
2.5) in Australian females, and 4.4 (3.5–5.2) in North
American females.
Rate comparisons, grouped by phenotypic character-
istics and ages of the probands, are provided in Table 3.
The incidence rates are higher in relatives of probands
who experienced melanoma at a young age. The rates
are also elevated, though more modestly and not
significantly, in relatives of probands who possess
known phenotypic characteristics associated with mel-
anoma risk, such as higher mole count, red hair,
propensity to burn in the sun, and propensity to tan.
Adjusted analyses using Poisson regression lead to
similar conclusions.
Finally, Figure 1 illustrates how these data can be
used to characterize the risks of melanoma in relatives of
a patient who has been diagnosed with the disease. The
figure displays the cumulative incidence in male (in
black) and female (in blue) relatives of cases diagnosed
in North America. The cumulative risk in a male relative
rises to 0.8% (0.5–1.1%) by age 50, 3.6% (2.7–4.6%) by
age 70, and 6.9% (5.0–8.8%) by age 80. The corre-
sponding cumulative risks in female relatives are 1.3%
(0.9–1.7%) by age 50, 4.0% (3.0–4.9%) by age 70 and
6.1% (4.6–7.6%) by age 80. The baseline rates for this
cohort, obtained using the 1990–1994 rates reported to
SEER, are 0.4%, 1.2% and 1.8% to ages 50, 70 and 80,
respectively, in men, and 0.4%, 0.8% and 1.1%,
respectively in women. These are plotted in red and
green in Figure 1.
Table 2. Incidence rates in relatives




Australia Male <30 4 77335 5 (0–10.2) 5
30–49 27 38305 70 (44–97) 33
50–69 29 20471 142 (90–193) 94
‡70 10 5232 191 (73–310) 183
North America Male <30 3 137733 2 (0–4.6) 2
30–49 17 68343 25 (13–37) 14
50–69 45 36095 125 (88–161) 36
‡70 23 9065 254 (150–357) 57
Australia Female <30 6 77034 8 (1.6–14) 7
30–49 23 38542 60 (35–84) 35
50–69 36 22049 163 (110–217) 64
‡70 11 7007 157 (64–250) 78
North America Female <30 3 136335 2 (0–4.7) 3
30–49 37 67692 55 (37–72) 15
50–69 39 37069 105 (72–138) 22
‡70 21 12601 167 (95–238) 24
a Excludes Italian cohort due to inadequate sample size.
b Number of melanomas among kin.
c Person-years follow-up.
d Rate per 100,000 person years (95% CI).
e Population rate per 100,000 person years for period 1990–94, obtained from weighted average of individual population rates, weighted by
numbers of probands from each population in the given region.
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Discussion
Our study provides insights into the nature of familial
aggregation of melanoma. A synthesis of eight published
case–control studies involving 2952 cases of melanoma
and 3618 controls provided a summary estimate of the
relative risk of melanoma in individuals with a ‘family
history’ of melanoma of 2.2 (1.8–2.9), where family
history was defined as the presence of one or more first
degree relatives [14]. Our analysis inverts this conven-
tional analytic strategy, by examining in detail the age-
and sex-specific incidence rates in first degree relatives of
melanoma cases, using relevant population rates of
melanoma as the benchmark. The resulting rate ratios,
or ‘familial relative risks’ in the terminology of Risch
[15], provide measures of the degree of familial aggre-
gation. In our study these range from 1.5 in the
Australian male cohort to 4.4 in the North American
female cohort. These span the results obtained in a
Table 3. Rates by phenotypic characteristics of probands






Age at diagnosis (proband)
‡70 68 251,926 31 1.0 1.0
50–69 141 256,392 55 1.8 (1.3–2.4) 1.6 (1.1–2.3)
30–49 117 201,448 107 3.4 (2.7–4.4) 3.1 (2.1–4.6)
<30 14 22,951 84 2.7 (1.5–4.7) 4.3 (2.0–9.3)
Mole count on back
<5 107 311,799 45 1.0 1.0
5–10 84 185,103 62 1.4 (1.0–1.8) 1.3 (0.9–1.9)
11–25 79 163,183 69 1.6 (1.1–2.1) 1.4 (0.9–2.0)
>25 63 145,088 61 1.4 (1.0–1.9) 1.2 (0.8–1.8)
Hair color
Dark brown/black 95 260,665 48 1.0 1.0
Light brown/blonde 192 478,705 54 1.1 (0.9–1.4) 1.0 (0.7–1.4)
Red 41 68,570 90 1.9 (1.3–2.6) 1.5 (0.9–2.5)
Eye color
Dark 54 161,202 46 1.0 1.0
Light 278 653,932 58 1.3 (0.9–1.7) 1.1 (0.8–1.9)
Freckles in childhood
None 123 337,450 46 1.0 1.0
Few 137 292,224 68 1.5 (1.2–1.9) 1.1 (0.9–1.6)
Many 52 98,336 75 1.6 (1.2–2.2) 1.0 (0.7–1.8)
Propensity to burn
No 171 453,420 51 1.0 1.0
Yes 163 359,815 64 1.3 (1.0–1.6) 1.1 (0.8–1.5)
Propensity to tan
Yes 183 476,211 52 1.0 1.0
No 152 336,736 63 1.2 (1.0–1.5) 1.2 (0.9–1.6)
a Rate per 100,000 person-years, standardized by sex, and by age to the USA population, 2000.
b Adjusted for all factors listed in addition to the sex and age at diagnosis of the relative, and residual familial clustering using Poisson
regression analysis
Fig. 1. The black and blue curves represent the estimated cumulative
incidence of melanoma in relatives of patients diagnosed with mela-
noma formale and female relatives, respectively. The baseline curves are
the corresponding cumulative risks of melanoma in North American
men and women (adapted from SEER incidence rates, 1990–94).
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recent population-based study in Sweden, where familial
relative risks of 2.4 and 3.0 were observed for offspring
and siblings, respectively [16]. However, in all settings
they represent substantial (and statistically significant)
familial aggregation. Risch has further shown that
under the assumption of an additive genetic model the
excess relative risk from these calculations (or more
specifically the excess in siblings) should be approxi-
mately one half of the excess relative risk in identical
twins, in which the relatives are genetically identical to
the probands, although there are no studies of twins
with sufficient data to estimate this quantity reliably. It
has also been shown that the excess relative risk in
identical twins should be smaller than the excess
standardized incidence ratio of second primary mela-
noma, with the difference being explainable by the effect
of environmental factors that do not aggregate in
families [17]. The overall excess standardized incidence
ratio of second primaries observed using SEER data is
indeed, at 7.5, more than double the excess familial
relative risk we have observed in this study.
Numerous previous case–control studies have dem-
onstrated consistent associations between ‘phenotypic’
characteristics and melanoma risk, and so it is of interest
to see if the familial aggregation is consistent with these
characteristics. Because of the nature of heritability,
relatives of patients with red hair, for example, will be
more likely than average to have red hair, but will
comprise individuals with a mixture of hair colors. Thus
the excess rate ratio in relatives of patients with red hair
should be attenuated. Indeed, for a single, known bi-
allelic variant there is a predictable relationship between
its relative risk (i.e. the value that would be obtained
from, say, a case–control study) and the rate ratio that
would be observed from studying the ratio of its
occurrences in first degree relatives of carriers and
non-carriers [8]. That is, the rate ratios comparing
factors such as hair color of probands in relatives will be
attenuated when compared with the relative risks
associated with hair color in conventional case–control
studies. Our results show that the phenotypic charac-
teristics exhibit substantial attenuation of effect. Most of
the observed associations are modest, and substantially
smaller in magnitude than those observed in
case–control studies. For example, in a meta-analysis
conducted by the International Melanoma Analysis
Group [4] the summary relative risks for red, light
brown and blond hair compared with brown/dark hair
were 2.4, 1.8 and 1.5 respectively, compared with
relative risks of 1.9 (1.5, adjusted) for red hair, and 1.1
(1.0, adjusted) for light hair in Table 3. Many studies
have examined the role of total nevus count or dysplas-
tic nevi count, and these studies have also consistently
demonstrated much stronger trends than exhibited in
Table 3 [18–26]. The observed attenuation of some of
these effects in the multivariate analysis using Poisson
regression may be due in part to the fact that nevi count
and other characteristics may be correlated [27, 28].
Also, it is unclear the extent to which variation in nevi
count is explainable by genetic factors, or by varying
exposure to the sun [29–32]. In a recent twin study the
heritability of nevus density has been shown to be in the
region of 65–68%, with evidence of a shared environ-
mental contribution [33, 34].
The strongest proband characteristic predicting risk in
relatives is age at diagnosis, with young probands
exhibiting substantially increased familial aggregation.
Again this is consistent with studies of the incidence of
second primary melanoma, and suggests that there is a
small subset of the population with very high risk
(resulting in multiple primaries in those individuals).
This risk variation is likely to be fully explained only
when the specific genetic variants contributing to the
variation in risk are identified.
Translation of these results into cumulative risks
demonstrates that the risk of melanoma in relatives of
cases is substantial. For example we estimate the cumu-
lative risk to age 80 to be 6.9% in male relatives of cases
diagnosed in North America. Taking into consideration
the adjusted rate ratio estimates from Table 3, the
cumulative risk to age 80 is estimated to be 10.8% in
male relatives of cases diagnosed under 50 years of age,
and 14.1% in male relatives of cases diagnosed at under
30 years of age. The corresponding cumulative risks to
age 80 in female relatives of North American cases are
6.1%, 9.5% and 12.4% respectively. Furthermore, since
the population incidence of melanoma has continued to
rise in the past decade the current risks in relatives may be
even higher than these estimates. Targeted screening of
high risk individuals on the basis of having a family
history of cancer has been advocated by Foon et al. [35],
who identified melanoma as one of several cancers with
evidence of strong familial aggregation. The Canadian
Task Force on Preventive Health Care has recommended
regular physical examination by a dermatologist for
individuals with a first degree relative with melanoma
[36]. The Australian Cancer Network/National Health
and Medical Research Council has stated that first-
degree relatives of melanoma cases should be advised of
the specific features that suggest melanoma, and offered
surveillance [37]. Conversely, the United States Preven-
tive Services Task Force did not find sufficient evidence
to recommend for or against screening for melanoma,
though their report did emphasize the fact that certain
subgroups of the population are at substantially in-
creased risk [38]. Our results help to clarify the degree of
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lifetime risk for first-degree relatives of a patient with
melanoma.
Our study has some limitations. First, the informa-
tion on family history of melanoma and other vital
statistics in the relatives was obtained solely from
proband interviews. No attempts have been made to
verify diagnoses of melanoma in the relatives. The
reporting of incident melanomas to cancer registries
has been shown to be more incomplete than for other
cancers, with only 88% reported to SEER within the
mandatory 19 month reporting period [39]. However,
the validity of family history data has been shown to
be considerably higher for first degree than for more
distant relatives, though it too varies by cancer site
[40]. A study of reporting of family history of
melanoma in Queensland, Australia, first with the
family members in question and, if confirmed by
them, then through their medical records, found lower
rates of agreement [41]. Thus, uncertainty exists about
both the reported familial cases and the population
rates used in our denominators. Furthermore the
proband was asked to give a best estimate of age at
diagnosis of the relative during the interview if the
exact age at diagnosis is unknown. Also, probands
may have better (or worse) recollection of information
about relatives with cancer than about relatives with
no known cancer, for example. A second limitation is
that the occurrences of cancer in the relatives took
place over a range of calendar time. Although the
majority occurred since 1985, even this time period
(1985–2000) is one in which secular changes in
population incidence rates have been substantial. Also,
these incidence trends have varied across the geo-
graphic regions of the GEM study [42, 43]. Conse-
quently there is an element of doubt about the
appropriate baseline rates to use in our estimates of
familial rate ratios. Third, the phenotypic characteris-
tics of the probands are all self-reported, and so these
are subject to misclassification also. The mole count,
in particular, was limited to the back, and probands
were asked to have these counted by a close relative,
friend, or spouse. Various studies have cast doubt on
the degree of accuracy of mole counts not conducted
by a dermatologist [44–46]. Good agreement, however,
has been found between several trained nurse observ-
ers counting moles on the backs of children and a
single observer counting them on photographs of the
backs, and inter-observer agreement was greatest for
counts on the backs [47]. A final limitation is the fact
that we cannot adjust for sun exposure history in
these analyses. Although extremely detailed sun expo-
sure history was collected on all probands in the
GEM study, no exposure data are available for the
relatives. Indeed some of the observed familial aggre-
gation may well be due to similarities of sun exposure
histories within families.
In summary, the study has confirmed the strong
aggregation of melanoma in families, as evidenced by
the high rates of melanoma in first-degree relatives of
patients with melanoma. Relatives of individuals with a
diagnosis of melanoma are themselves at substantially
elevated risk, especially relatives of cases with a young
age at diagnosis, and they represent an important
potential target for focussed cancer prevention strate-
gies.
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